Anke van Engen, Senior Director, Consulting at Quintiles discusses statistical issues in analysing data to meet HTA authorities needs as they assess oncology products.  She highlights variations in approaches by different national authorities and how complex statistical methods can be used to ensure data quality for studies in which patients change treatment during the trial period.